nach oben

Erschienen in:

01.10.2023 | News item

Compounded ketamine products: potential risks of at-home use

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

The US FDA is warning patients and healthcare providers about risks associated with use of compounded ketamine products for the treatment of psychiatric disorders. …

FDA warns patients and health care providers about potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders Internet Document : 10 Oct 2023. Available from: URL: https://www.fda.gov/drugs/human-drug-compounding/fda-warns-patients-and-health-care-providers-about-potential-risks-associated-compounded-ketamine

Titel: Compounded ketamine products: potential risks of at-home use
Publikationsdatum: 01.10.2023
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-47729-y

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Compounded ketamine products: potential risks of at-home use

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Etomidate/fentanyl

Aciclovir/antiepileptic drugs/dexamethasone

Adenosine

Rivoceranib

Gemcitabine/paclitaxel

Baricitinib/dexamethasone/remdesivir